+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cardiomyopathy Drug"

From
Cardiomyopathy Therapies - Global Strategic Business Report - Product Thumbnail Image

Cardiomyopathy Therapies - Global Strategic Business Report

  • Report
  • March 2025
  • 250 Pages
  • Global
From
From
From
From
Dilated Cardiomyopathy (DCM) - Epidemiology Forecast - 2034 - Product Thumbnail Image

Dilated Cardiomyopathy (DCM) - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 80 Pages
  • Global
From
Dilated Cardiomyopathy - Pipeline Insight, 2024 - Product Thumbnail Image

Dilated Cardiomyopathy - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Ischemic Cardiomyopathy - Pipeline Insight, 2024 - Product Thumbnail Image

Ischemic Cardiomyopathy - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Gene Therapies For Cardiomyopathies - Pipeline Insight, 2024 - Product Thumbnail Image

Gene Therapies For Cardiomyopathies - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Hypertrophic Cardiomyopathy - Pipeline Insight, 2024 - Product Thumbnail Image

Hypertrophic Cardiomyopathy - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Obstructive Hypertrophic Cardiomyopathy (HCM) - Pipeline Insight, 2024 - Product Thumbnail Image

Obstructive Hypertrophic Cardiomyopathy (HCM) - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Pipeline Insight, 2024 - Product Thumbnail Image

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 40 Pages
  • Global
From
ATTR Cardiomyopathy Treatment Market - Product Thumbnail Image

ATTR Cardiomyopathy Treatment Market

  • Report
  • May 2024
  • 200 Pages
  • Global
From
Hypertrophic Cardiomyopathy Treatment Market Report 2025 - Product Thumbnail Image

Hypertrophic Cardiomyopathy Treatment Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report 2025 - Product Thumbnail Image

Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
Diabetic Cardiomyopathy - Pipeline Insight, 2024 - Product Thumbnail Image

Diabetic Cardiomyopathy - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Transthyretin Amyloid Cardiomyopathy - Pipeline Inisght, 2021 - Product Thumbnail Image

Transthyretin Amyloid Cardiomyopathy - Pipeline Inisght, 2021

  • Clinical Trials
  • September 2021
  • 60 Pages
  • Global
From
Loading Indicator

The Cardiomyopathy Drug market is a subset of the Cardiovascular Drugs market, focusing on drugs used to treat cardiomyopathy, a condition in which the heart muscle becomes weakened or damaged. These drugs are used to reduce symptoms, improve heart function, and reduce the risk of complications. Commonly used drugs include beta-blockers, ACE inhibitors, angiotensin receptor blockers, and diuretics. Other treatments may include lifestyle changes, such as diet and exercise, and surgery. The Cardiomyopathy Drug market is highly competitive, with many companies offering a variety of treatments. Major players in the market include Pfizer, Novartis, Sanofi, Merck, and GlaxoSmithKline. Other companies include AstraZeneca, Bristol-Myers Squibb, and Boehringer Ingelheim. Show Less Read more